David Ege
About David Ege
David Ege is the EVP, Chief Technology Officer at Merck, with over 15 years of experience in the pharmaceutical industry, specializing in vaccine and biologics manufacturing.
David Ege's Role as EVP and Chief Technology Officer
David Ege currently serves as the Executive Vice President and Chief Technology Officer. In this role, he leverages his extensive experience in the pharmaceutical industry to oversee technological initiatives and drive innovation. His responsibilities likely include steering technological advancements and ensuring the efficacy of manufacturing processes.
David Ege's Experience in the Pharmaceutical Industry
David Ege has over 15 years of experience in the pharmaceutical industry. His career focuses on vaccine and biologics manufacturing, as well as facility development and process optimization. Ege's background includes significant contributions to improving manufacturing procedures and advancing pharmaceutical technologies to meet industry standards.
David Ege's Career at Merck
David Ege has been with Merck since 2003, where he has held various technical and leadership roles in R&D and manufacturing. His work has spanned both the United States and Switzerland. From 2015 to 2019, he served as Executive Director of Vaccines & Biologics Manufacturing at Merck's plant in Elkton, VA. In this position, he led bulk manufacturing operations for several key products, including Gardasil, Gardasil9, and Cancidas.
David Ege's Contributions to Vaccine Development
David Ege played a crucial role in the successful first-in-class licensure and launch of several high-impact vaccines and therapeutics. His efforts contributed to the introduction of Gardasil in 2006, Gardasil9 in 2014, and the breakthrough cancer immunotherapy, Keytruda, in 2014. These contributions have had a significant impact on public health and cancer treatment.
David Ege's Educational Background
David Ege graduated summa cum laude from Princeton University with a Bachelor of Science in Engineering (BSE) in chemical engineering. He later earned his Ph.D. in chemical engineering from the University of Pennsylvania. During his time at the University of Pennsylvania, he worked in the Center for Technology Transfer and served as President of the Penn Biotech Group.